86. Pulmonary arterial hypertension
1,083 clinical trials,   667 drugs   (DrugBank: 122 drugs),   98 drug target genes,   185 drug target pathways

Searched query = "Pulmonary arterial hypertension", "PAH", "IPAH", "HPAH", "Eisenmenger syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-024585-22-DE
(EUCTR)
01/12/201617/08/2016What is the effect of intravenous iron supplementation on cardiopulmonary haemodynamics, exercise capacity and quality of life in patients with IPAH and iron deficiency?What is the effect of intravenous iron supplementation on cardiopulmonary haemodynamics, exercise capacity and quality of life in patients with IPAH and iron deficiency? - Ferinject® for iron deficiency in IPAH patients Idiopathic or familial pulmonary arterial hypertension
MedDRA version: 19.0;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Ferinject
Product Name: Ferinject
INN or Proposed INN: FERRIC CARBOXYMALTOSE
Imperial College Academic Healthsciences CentreNULLNot RecruitingFemale: yes
Male: yes
60Phase 2Germany;United Kingdom
2NCT01847352
(ClinicalTrials.gov)
February 20131/5/2013Iron Status and Hypoxic Pulmonary Vascular ResponsesEffect of Endogenous Iron Status on Hypoxic Pulmonary Vascular Responses and Their Attenuation by Intravenous IronLung Hypoxia;Pulmonary Arterial Hypertension;Iron DeficiencyDrug: Intravenous administration of ferric carboxymaltose;Other: Subacute hypoxic exposuresUniversity of OxfordNational Institute for Health Research, United Kingdom;British Heart FoundationCompleted18 YearsN/ABoth31N/AUnited Kingdom
3EUCTR2010-023233-30-NL
(EUCTR)
13/12/201006/10/2010‘Intravenous iron treatment in iron deficient patients with pulmonary arterialhypertension' - Treating iron deficiency in PAH‘Intravenous iron treatment in iron deficient patients with pulmonary arterialhypertension' - Treating iron deficiency in PAH Objective: To evaluate the effects of intravenous iron suppletion in iron deficient IPAH patients.Study design: Intervention studyStudy population: Patients with idiopathic pulmonary arterial hypertension (IPAH) and iron deficiencyIntervention:Patients receive a weekly iron bolus infusion until iron levels are restored (correction phase). Then a maintenance dose is given once per month (maintenance phase) until the endpoint after 20 weeks.
MedDRA version: 12.1;Level: LLT;Classification code 10064909;Term: Idiopathic (IPAH)
Trade Name: Ferinject
Product Name: Ferric carboxymaltose
Product Code: RVG 33865
VU university medical centerNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
30Netherlands